Skip to content

Preventing the Return of Depression in Elderly Patients

Maintenance Therapies in Late-Life Depression

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000377
Enrollment
Unknown
Registered
1999-11-03
Start date
1989-03-31
Completion date
2000-04-30
Last updated
2013-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Aged, Antidepressive Agents, Depression, Dose-Response Relationship, Drug, Female, Human, Male, Middle Age, Nortriptyline, Placebos, Recurrence, Aged, 80 and over, Antidepressive Agents -- *therapeutic use, Antidepressive Agents -- administration & dosage, Depression -- *drug therapy, Nortriptyline -- *therapeutic use, Nortriptyline -- administration & dosage

Brief summary

The purpose of this study is to compare the effectiveness of two doses of nortriptyline in elderly patients whose depression returned after stopping treatment. Nortriptyline is an antidepressant. This study enrolls patients who were treated for depression in an earlier research study and whose depression has returned since stopping treatment. Patients are treated for 4 months to bring the depression under control. Patients are then assigned randomly (like tossing a coin) to receive either the full dose of nortriptyline or half the usual dose of nortriptyline. Patients continue taking nortriptyline for 2 years or until a major depression returns. Throughout the study, patients are monitored for symptoms of depression and other side effects.

Detailed description

To determine whether elderly (60-80 years old) depressed patients who cannot sustain a remission without medication must be maintained at full acute-treatment dose. To compare the efficacy of full-dose vs half-dose nortriptyline (NT) in preventing recurrences of major depression in the elderly. To determine whether those patients who experience a recurrence while in a maintenance placebo condition (Study I) require 100 percent of their acute-treatment dose of NT to prevent subsequent recurrences or can be successfully maintained on 50 percent of their acute-treatment dose (Study II). Investigators expect a pool of 60 patients from Study I to become eligible for Study II (the full-dose/half-dose maintenance trial). After treatment of the recurrence and following 16 weeks of stabilization therapy, patients are randomized to 1 of 2 maintenance therapy cells: full-dose NT or half-dose NT. Maintenance lasts 2 years or until recurrence of major depression. The following are assessed: differences in recurrence rates and time to recurrence under full-dose vs half-dose conditions; differences in symptomatic ratings of depression, suicidal ideation, social adjustment, and side effects; and differences in compliance rates as determined by variability in level-to-dose (L/D) ratios. Exploratory data analyses are used to generate a hypothetical profile of elderly patients who can remain well on half-dose maintenance nortriptyline. For information on related studies, please follow these links: http://clinicaltrials.gov/show/NCT00178100 http://clinicaltrials.gov/show/NCT00177671

Interventions

DRUGNortriptyline

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
60 Years to 80 Years

Inclusion criteria

\- Patients must have: Recurrence of major depression while in a maintenance placebo condition in the currently funded maintenance therapy protocol (Study I).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026